New Zacks SCR report on RVX came out today from John D. Vandermosten entitled "Price Target Up; More BETonMACE Sites Opening."
Price target increased to $6.50. BETonMACE study sites in Taiwan, China and Russia are anticipated to open in June, though no clarity on US site addition in the report. Phase 2 Renal studies to commence in H1 2017.